CN103124739B - 一种新胰高血糖素样肽类似物、组合物及其用途 - Google Patents

一种新胰高血糖素样肽类似物、组合物及其用途 Download PDF

Info

Publication number
CN103124739B
CN103124739B CN201080066828.7A CN201080066828A CN103124739B CN 103124739 B CN103124739 B CN 103124739B CN 201080066828 A CN201080066828 A CN 201080066828A CN 103124739 B CN103124739 B CN 103124739B
Authority
CN
China
Prior art keywords
xaa
natural
glp
histidine
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080066828.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103124739A (zh
Inventor
胡邵京
谭芬来
王燕萍
马存波
胡云雁
曹红
赵向东
龙伟
王印祥
丁列明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Beta Pharma Inc
Original Assignee
Zhejiang Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc, Betta Pharmaceuticals Co Ltd filed Critical Zhejiang Beta Pharma Inc
Publication of CN103124739A publication Critical patent/CN103124739A/zh
Application granted granted Critical
Publication of CN103124739B publication Critical patent/CN103124739B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CN201080066828.7A 2010-05-17 2010-05-17 一种新胰高血糖素样肽类似物、组合物及其用途 Active CN103124739B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/000692 WO2011143788A1 (en) 2010-05-17 2010-05-17 Novel glucagon like peptide analogs, composition, and method of use

Publications (2)

Publication Number Publication Date
CN103124739A CN103124739A (zh) 2013-05-29
CN103124739B true CN103124739B (zh) 2015-11-25

Family

ID=44991143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080066828.7A Active CN103124739B (zh) 2010-05-17 2010-05-17 一种新胰高血糖素样肽类似物、组合物及其用途

Country Status (13)

Country Link
US (1) US9487570B2 (enExample)
EP (1) EP2571897B1 (enExample)
JP (1) JP5819946B2 (enExample)
KR (1) KR101609302B1 (enExample)
CN (1) CN103124739B (enExample)
AU (1) AU2010353685B2 (enExample)
BR (1) BR112012029248B1 (enExample)
CA (1) CA2802931C (enExample)
ES (1) ES2528496T3 (enExample)
RU (1) RU2557301C2 (enExample)
SG (1) SG185604A1 (enExample)
WO (1) WO2011143788A1 (enExample)
ZA (1) ZA201209566B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134284A1 (zh) * 2010-04-27 2011-11-03 浙江贝达药业有限公司 胰高血糖素样肽-1类似物及其应用
EP2820424B1 (en) 2012-01-24 2016-12-07 University of Massachusetts Soluble manf in pancreatic beta-cell disorders
WO2019082138A1 (en) * 2017-10-27 2019-05-02 Lorven Biologics Private Limited PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN110862448A (zh) * 2019-11-21 2020-03-06 浙江大学 两性离子多肽修饰的glp-1衍生物及其制备方法和应用
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
CN115124596A (zh) * 2021-12-24 2022-09-30 浙江和泽医药科技股份有限公司 一种全固相合成醋酸亮丙瑞林的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033672A2 (en) * 2001-10-19 2003-04-24 Riken Nr3b nmda receptor subunit compositions and related methods
CN1683408A (zh) * 2004-04-14 2005-10-19 贝达医药开发(上海)有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
WO2007031519A2 (en) * 2005-09-15 2007-03-22 Air Liquide Sante (International) Antimicrobial preparations having a content of octenidine dihydrochloride encapsulated in liposomes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE60137876D1 (de) * 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
GEP20063908B (en) 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1494704A1 (en) * 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7557183B2 (en) * 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
EP1709071A4 (en) * 2004-01-08 2007-05-30 Theratechnologies Inc GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE
CN100535006C (zh) * 2004-09-06 2009-09-02 上海华谊生物技术有限公司 Glp-1类似物
JP2008525452A (ja) * 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
SI1881850T1 (sl) * 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
CA2621699A1 (en) * 2005-09-08 2007-03-15 Trustees Of Tufts College Stabilized glp-1 analogs
EP2007804B1 (en) * 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
CN101668535B (zh) * 2006-12-29 2017-07-28 益普生制药股份有限公司 Glp‑1药物组合物
ATE515943T1 (de) * 2007-09-07 2011-07-15 Janssen Pharmaceutica Nv Kombinationen aus pyrimethanil und silberverbindungen
GB0717399D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033672A2 (en) * 2001-10-19 2003-04-24 Riken Nr3b nmda receptor subunit compositions and related methods
CN1683408A (zh) * 2004-04-14 2005-10-19 贝达医药开发(上海)有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
WO2007031519A2 (en) * 2005-09-15 2007-03-22 Air Liquide Sante (International) Antimicrobial preparations having a content of octenidine dihydrochloride encapsulated in liposomes

Also Published As

Publication number Publication date
CN103124739A (zh) 2013-05-29
JP2013527178A (ja) 2013-06-27
AU2010353685A8 (en) 2013-05-09
US20130203672A1 (en) 2013-08-08
US9487570B2 (en) 2016-11-08
AU2010353685B2 (en) 2014-09-25
KR20130039740A (ko) 2013-04-22
CA2802931C (en) 2016-10-04
AU2010353685A1 (en) 2013-01-10
ES2528496T3 (es) 2015-02-10
RU2012154322A (ru) 2014-06-27
ZA201209566B (en) 2013-08-28
EP2571897A1 (en) 2013-03-27
BR112012029248A2 (pt) 2020-06-02
EP2571897A4 (en) 2013-11-06
WO2011143788A1 (en) 2011-11-24
SG185604A1 (en) 2012-12-28
BR112012029248B1 (pt) 2021-09-28
JP5819946B2 (ja) 2015-11-24
RU2557301C2 (ru) 2015-07-20
CA2802931A1 (en) 2011-11-24
EP2571897B1 (en) 2014-11-05
KR101609302B1 (ko) 2016-04-06

Similar Documents

Publication Publication Date Title
KR101205272B1 (ko) 아실화된 ｇｌｐ-1 화합물
KR101241862B1 (ko) 신규 ｇｌｐ-1 유도체
US20090062192A1 (en) Dimeric Peptide Agonists of the Glp-1 Receptor
US9920106B2 (en) GLP-1 compounds
CN103189389B (zh) 新的glp‑ⅰ类似物及其制备方法和用途
US20090005312A1 (en) Novel glp-1 analogues linked to albumin-like agents
JP5819946B2 (ja) 新規のグルカゴン様ペプチド類似体、組成物、および使用方法
JP2008533106A (ja) 伸長されたｇｌｐ−１化合物
KR20110017874A (ko) 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
EP3842061A1 (en) Stapled triazole co-agonists of the glucagon and glp-1 receptors
CN100503637C (zh) 胰高血糖素样肽类似物、其组合物及其使用方法
TWI428139B (zh) A novel glucagon-like peptide analogue, a composition and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: 311100 No. 589 Hongfeng Road, Yuhang Economic Development Zone, Zhejiang, Hangzhou, China

Applicant after: Beta Pharmaceutical Co., Ltd.

Applicant after: Hu Shaojing

Address before: 311100 No. 589 Hongfeng Road, Yuhang Economic Development Zone, Zhejiang, Hangzhou, China

Applicant before: Zhejiang Beta Pharmacy Inc.

Applicant before: Hu Shaojing

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ZHEJIANG BETA PHARMA CO., LTD. TO: BETA PHARMACEUTICAL CO., LTD.

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: HU SHAOJING

Effective date: 20140303

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20140303

Address after: 311100 No. 589 Hongfeng Road, Yuhang Economic Development Zone, Zhejiang, Hangzhou, China

Applicant after: Beta Pharmaceutical Co., Ltd.

Address before: 311100 No. 589 Hongfeng Road, Yuhang Economic Development Zone, Zhejiang, Hangzhou, China

Applicant before: Beta Pharmaceutical Co., Ltd.

Applicant before: Hu Shaojing

C14 Grant of patent or utility model
GR01 Patent grant